Litigation Update: FDA Orders for an Immediate Removal of Zantac from the Market

On April 1^st, the FDA announced a global halt of heartburn medication ranitidine, sold under the brand name of Zantac. This follows an initial warning back in September 2019, when low levels of a toxic compound and probable human carcinogen, NDMA (N-nitrosodimethylamine), was found in the medication. The decision to remove all medications from shelves and stop its production came from recent studies that showed that some impurities in the products are altered if the medications are stored above room temperature.  Given that it is hard to establish how and for how long the products have been stored, the FDA decided for a full recall. Patients who are currently on the medication are to stop taking it and replace with other existent options that do not have the NDMA compound and consult with their doctors if they are on prescription ranitidine. Additionally, patients should not bring back their current Zantac medicines to the store given the coronavirus but follow FDA’s safe disposal instructions. Both Pfizer and Sanofi face litigation for Zantac allegedly causing cancer. Click on this link for information on Verus’ Mass Tort Services. To contact us, fill out this form or email us at info@verusllc.com and we will reply immediately. |CONTACT US| |REQUEST PROPOSAL|

https://www.forlawfirmsonly.com/litigation-update-fda-orders-for-an-immediate-removal-of-zantac-from-the-market/